Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Scopus BioPharma's Total Liabilities for the quarter that ended in Jun. 2023 was $11.00 Mil. Scopus BioPharma's Total Assets for the quarter that ended in Jun. 2023 was $0.50 Mil.
Therefore, Scopus BioPharma's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2023 was 22.09.
Scopus BioPharma Liabilities-to-Assets Historical Data
The historical data trend for Scopus BioPharma's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Scopus BioPharma's Liabilities-to-Assets
For the Biotechnology subindustry, Scopus BioPharma's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scopus BioPharma's Liabilities-to-Assets Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scopus BioPharma's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Scopus BioPharma's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Scopus BioPharma's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2022 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Scopus BioPharma Liabilities-to-Assets Related Terms
Thank you for viewing the detailed overview of Scopus BioPharma's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Scopus BioPharma (Scopus BioPharma) Business Description
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCPS has been successfully added to your 